(9S)-9-[(9R)-2-Carboxy-4-hydroxy-10-oxo-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid | 81-27-6

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: (9S)-9-[(9R)-2-Carboxy-4-hydroxy-10-oxo-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
• CAS: 81-27-6
• 化学式: C₄₂H₃₈O₂₀
• 分子量: 862.7
• InChiKey: IPQVTOJGNYVQEO-DBHPJPNJSA-N

物化性质

• 熔点：
  >191oC (dec.)
• 比旋光度：
  D20 -164° (c = 0.1 in 60% acetone); D20 -147° (c = 0.1 in 70% acetone); D20 -24° (c = 0.2 in 70% dioxane)
• 沸点：
  1144.8±65.0 °C(Predicted)
• 密度：
  1.743±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于水基（轻微、加热）、DMSO（轻微、加热）
• LogP：
  1.880 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  62
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  348
• 氢给体数：
  12
• 氢受体数：
  20

安全信息

• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  29173990
• 安全说明：
  S22,S45
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

Sennoside A (NSC 112929) 是从大黄根茎中分离得到的一种刺激性泻药，在肠道中引起通便作用。

靶点

Target	Value
MAO	17 μM

体外研究

Sennoside A，一种从大黄根茎中分离得到的刺激性泻药，通过调节结肠的自发性运动而具有通便作用。它轻微调节牛血清单胺氧化酶，IC50为17 μM。

体内研究

• LD50：小鼠和大鼠均为5000毫克/千克（灌胃）。

化学性质

Sennoside A 是一种黄色结晶粉末，可溶于甲醇、乙醇、DMSO等有机溶剂。它来源于番泻叶和大黄。

用途

• 含量测定/鉴定/药理实验：用于药物成分的检测与验证。
• 药理药效：常用于治疗热结积滞、便秘腹痛、水肿胀满，是临床上常用的泻下药之一。番泻甙具有清热行滞、通便利水、排毒养颜的功效，并且还具有一定的抗菌功能，可用于急性胰腺炎、菌痢、流行性出血热、胆囊炎及产后回乳等。

用途（草药产品分析标准品）

Sennoside A 也用作草药产品的标准品。

文献信息

• REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF
  申请人：RATAN Rajiv

  公开号：US20130005666A1

  公开（公告）日：2013-01-03

  The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
• Therapeutic Compounds
  申请人：University of Iowa Research Foundation

  公开号：US20130225517A1

  公开（公告）日：2013-08-29

  The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
• Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
  申请人：Yale University

  公开号：US20150272939A1

  公开（公告）日：2015-10-01

  The present invention includes a novel high-throughput screen capable of identifying compounds that inhibit JARID1B demethylase activity or JARID1A demethylase activity. The present invention further includes novel inhibitors of JARID1B demethylase activity and/or JARID1A demethylase activity, and methods using the same.
• US9200046B2
  申请人：——

  公开号：US9200046B2

  公开（公告）日：2015-12-01